Research analysts at Zacks Research started coverage on shares of TRex Bio (NASDAQ:TRXB – Get Free Report) in a report issued on Tuesday, Zacks reports. The brokerage set a “hold” rating on the stock.
A number of other equities analysts have also recently weighed in on TRXB. Cantor Fitzgerald assumed coverage on shares of TRex Bio in a research report on Tuesday. They set an “overweight” rating for the company. Evercore began coverage on shares of TRex Bio in a report on Tuesday. They issued a “strong-buy” rating for the company. JPMorgan Chase & Co. assumed coverage on TRex Bio in a research report on Tuesday. They issued an “overweight” rating and a $20.00 target price on the stock. Stifel Nicolaus assumed coverage on TRex Bio in a research note on Tuesday. They set a “buy” rating and a $39.00 price target on the stock. Finally, Wedbush initiated coverage on TRex Bio in a research note on Monday. They set an “outperform” rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $29.67.
Check Out Our Latest Research Report on TRex Bio
TRex Bio Price Performance
TRex Bio stock opened at $13.55 on Tuesday. TRex Bio has a 1 year low of $12.50 and a 1 year high of $16.56.
Insiders Place Their Bets
In other TRex Bio news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the purchase, the insider directly owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
About TRex Bio
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.
See Also
- Five stocks we like better than TRex Bio
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.
